A phase I study of the safety and pharmacokinetics of DNIB0600A, an anti-NaPi2b antibody-drug-conjugate (ADC), in patients (pts) with non− small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (OC).
Michael S. Gordon
Research Funding - Genentech
David E. Gerber
Research Funding - Genetic Technologies
Jeffrey R. Infante
No relevant relationships to disclose
Jian Xu
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
David S. Shames
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Younjeong Choi
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Robert S. Kahn
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Kedan Lin
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Katie Wood
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Daniel J. Maslyar
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Howard A. Burris
No relevant relationships to disclose